Welcome to our dedicated page for DBV Technologies S.A. news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on DBV Technologies S.A. stock.
DBV Technologies S.A. (symbol: DBVT) is a clinical-stage specialty biopharmaceutical company revolutionizing the treatment of food allergies, a significant and growing public health issue. Founded in 2002, the company has developed a groundbreaking technology platform known as Viaskin®.
Viaskin® employs epicutaneous immunotherapy (EPIT), a proprietary method that administers allergens through an epicutaneous patch applied to intact skin. This innovative approach targets Langerhans cells, specialized immune cells in the skin, which capture the allergen and migrate to the lymph nodes. This mechanism allows for activation of the immune system without introducing the allergen into the bloodstream, thus minimizing systemic exposure and the risk of severe allergic reactions.
DBV Technologies' flagship product, Viaskin Peanut, is designed for peanut-allergic patients. The patch aims to improve patient tolerability to peanuts and significantly reduce the risk of life-threatening allergic reactions upon accidental exposure. Clinical trials have demonstrated the product's efficacy and safety, making it a promising solution for millions of individuals affected by peanut allergies.
In addition to peanut allergies, DBV Technologies is expanding its portfolio to address other food allergies like milk. The company's robust pipeline and innovative approach position it at the forefront of allergy treatment research.
DBV Technologies has secured multiple worldwide patents for its Viaskin® technology, underlining its pioneering role in the field of immunotherapy. The company continually collaborates with leading research institutions and partners to advance its clinical programs and bring new therapies to market.
Recent achievements include significant milestones in clinical trials, regulatory submissions, and strategic partnerships, reflecting DBV Technologies' commitment to developing safe and effective treatments for food allergies. The company's dedication to addressing unmet medical needs ensures it remains a crucial player in the biopharmaceutical landscape.
DBV Technologies announced the filing of its 2021 Annual Report on Form 10-K with the SEC and its 2021 Universal Registration Document with the French AMF. Both documents are accessible on the company's investor website and the respective regulatory authority sites. DBV Technologies is focused on developing the Viaskin™ platform for food allergies using epicutaneous immunotherapy, with ongoing trials for Viaskin Peanut. The company operates globally from Montrouge, France, and Summit, NJ, and its shares are listed on Euronext and Nasdaq under the ticker DBVT.
DBV Technologies reported its 2021 financial results, revealing a net loss of $97.8 million, down from $159.6 million in 2020. The company's cash and cash equivalents decreased to $77.3 million from $196.4 million in 2020. Operating income fell to $5.7 million, primarily due to reduced revenue from a collaboration with Nestlé. However, DBV extended its cash runway into Q1 2023 through cost containment measures. The pivotal protocol for the modified Viaskin Peanut patch is complete and ready for FDA submission, highlighting ongoing discussions with the FDA aimed at advancing its research and development efforts.
DBV Technologies will report its full year 2021 financial results on March 3, 2022. The company, based in Montrouge, France, is focused on developing the Viaskin platform for immunotherapy, specifically for food allergies. A conference call will be held at 5:00 p.m. ET to discuss the financial outcomes and provide corporate updates. The call can be accessed via specified teleconferencing numbers and a live audio webcast will be available on their website.
DBV Technologies (DBVT) will participate in the AAAAI 2022 Congress from February 24-28, 2022. They will present two scientific posters: one on allergy specialty care effects on healthcare utilization in children with peanut allergies and another on pooled safety data from Phase 3 trials of their Viaskin Peanut treatment. Viaskin Peanut aims to reduce allergic reactions in children aged 4-11. The presentations will be available on-demand for registered attendees and later on DBV's website.
DBV Technologies announced that CEO Daniel Tassé will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18 at 8:40 am ET. This event will be hosted in a virtual format, allowing interested parties to access the webcast through the Investors & Media section of the Company’s website. A replay will be available after the event.
DBV Technologies, based in Montrouge, France, focuses on developing Viaskin™, a proprietary technology for food allergy treatment. The Company's shares trade under the ticker DBVT on Nasdaq.
DBVT released its monthly report on voting rights and share count as of January 31, 2022. The total number of shares stood at 55,095,762, with the total gross of voting rights also at 55,095,762. The net voting rights, after accounting for shares without voting rights, totaled 54,925,155. This information ensures transparency for investors and complies with regulations set by the Autorité des Marchés Financiers.
DBV Technologies has published its Half-Year Report on the liquidity contract with ODDO BHF as of December 31, 2021.
The liquidity account contained 153,631 shares worth €175,542.33, compared to 24,313 shares and €682,454.94 at the contract's inception in July 2018. In 2021's second half, 1,206 shares were purchased and 1,065 sold, totaling 455,657 shares bought for €3,256,011.54 and 379,901 sold for €2,951,075.39. DBV is advancing Viaskin™, a non-invasive immunotherapy platform targeting food allergies.
DBVT announced its monthly update on voting rights and total shares as of December 31, 2021. The total number of shares outstanding is 55,095,762, while the total gross of voting rights stands at 55,095,762. After accounting for shares without voting rights, the total net voting rights reach 54,942,131. This information complies with the regulations of the Autorité des Marchés Financiers.
DBV Technologies announced that CEO Daniel Tassé will participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference. The event will be available for on-demand viewing starting January 10, 2022, at 7:00 AM ET. Investors can access the webcast on the company's website, where a replay will also be available post-event. DBV Technologies is focused on developing Viaskin™, an innovative immunotherapy platform aimed at treating food allergies, with ongoing clinical trials for Viaskin Peanut.
DBV Technologies announced plans to begin a pivotal Phase 3 study for its modified Viaskin Peanut patch aimed at children. This follows FDA feedback suggesting a sequential development approach, which DBV deemed inefficient. Instead, the company will conduct a Phase 3 placebo-controlled trial to demonstrate the patch's safety and effectiveness. In parallel, DBV has withdrawn its Marketing Authorization Application for Viaskin Peanut from the EMA due to insufficient data from a single pivotal study. The company believes that new data will better support its application for regulatory approval.
FAQ
What is the current stock price of DBV Technologies S.A. (DBVT)?
What is the market cap of DBV Technologies S.A. (DBVT)?
What does DBV Technologies S.A. specialize in?
What is Viaskin® technology?
What is Viaskin Peanut?
How does Viaskin® technology minimize the risk of allergic reactions?
What other food allergies is DBV Technologies targeting?
When was DBV Technologies founded?
What are some recent achievements of DBV Technologies?
What is the significance of DBV Technologies' patents?
How does DBV Technologies collaborate with other institutions?
What is the financial condition of DBV Technologies?
